Envestnet Asset Management
KZIA

Envestnet Asset Management’s Kazia Therapeutics KZIA Stock Holding History

Envestnet Asset Management’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-528
Closed -$111K – 3977
2022
Q2 		$111K Hold
528
– – ﹤0.01% 3744
2022
Q1 		$202K Hold
528
– – ﹤0.01% 3680
2021
Q4 		$223K Buy
+528
New +$263K ﹤0.01% 3601

Other funds holding KZIA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Envestnet Asset Management's KZIA Position: Q3 2022 in Review

Envestnet Asset Management sold out of Kazia Therapeutics (KZIA) in Q3 2022, closing a stake of 528 shares — an estimated $111K sold.

Envestnet Asset Management first reported a position in KZIA in Q4 2021 and held it in 3 quarters. The position peaked at $223K in Q4 2021. 8 funds tracked by Wall St. Rank hold KZIA as of Q3 2022.

  • Envestnet Asset Management reported no remaining Kazia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Envestnet Asset Management sold 528 Kazia Therapeutics shares in Q3 2022, an estimated $111K.
  • Envestnet Asset Management first reported a position in Kazia Therapeutics in Q4 2021 and held it in 3 quarters.
  • Envestnet Asset Management's Kazia Therapeutics position peaked at $223K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q3 2022.

Based on Envestnet Asset Management's 13F filing for Q3 2022, filed 10 Nov 2022.